1. Home
  2. SPRO vs ROC Comparison

SPRO vs ROC Comparison

Compare SPRO & ROC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

SPRO

Spero Therapeutics Inc.

N/A

Current Price

$1.14

Market Cap

71.0M

Sector

Health Care

ML Signal

N/A

Logo Rank One Computing Corporation Common stock

ROC

Rank One Computing Corporation Common stock

N/A

Current Price

$4.36

Market Cap

78.6M

Sector

N/A

ML Signal

N/A

Company Overview

Basic Information
Metric
SPRO
ROC
Founded
2013
2015
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
71.0M
78.6M
IPO Year
2017
2025

Fundamental Metrics

Financial Performance
Metric
SPRO
ROC
Price
$1.14
$4.36
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$9.00
AVG Volume (30 Days)
355.5K
18.0K
Earning Date
05-13-2026
03-31-2026
Dividend Yield
N/A
N/A
EPS Growth
111.81
N/A
EPS
N/A
N/A
Revenue
$66,802,000.00
$16,979,679.00
Revenue This Year
N/A
N/A
Revenue Next Year
$300.00
N/A
P/E Ratio
N/A
N/A
Revenue Growth
39.24
23.90
52 Week Low
$1.08
$3.71
52 Week High
$3.08
$7.80

Technical Indicators

Market Signals
Indicator
SPRO
ROC
Relative Strength Index (RSI) 32.01 47.39
Support Level $1.13 $4.14
Resistance Level $1.29 $4.43
Average True Range (ATR) 0.04 0.17
MACD 0.01 0.04
Stochastic Oscillator 15.53 59.80

Price Performance

Historical Comparison
SPRO
ROC

About SPRO Spero Therapeutics Inc.

Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing, and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. It is also focused on SPR206, a next-generation polymyxin investigational product candidate being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.

About ROC Rank One Computing Corporation Common stock

Rank One Computing Corp is an American artificial intelligence company. It develops AI systems that analyze visual data to identify and interpret objects and activities. The company's focus is on biometric identity, digital forensics, and real-time video analytics. It uses the term 'Vision AI,' which is an operational AI built for accuracy, speed, and auditability. The company generates revenue from the sale of access to its software platforms, maintenance services, and professional services.

Share on Social Networks: